Evonik has recorded third quarter sales up 4% to EUR3.4bn (US$3.7bn), with adjusted EBITDA increasing by what the company terms “considerably” year-on-year to EUR653m.
"Evonik remains successful," said Evonik chairman, Klaus Engel. "Our business is continuing to develop at a high level in the second half of the year. It is also pleasing to report all three chemical segments were able to increase their earnings year-on-year in the third quarter.
“Building on that and on our belief in our performance, we are looking ahead with confidence."
At Group level, both sales and adjusted EBITDA continued the performance seen in the first two quarters of the year, while global demand for Evonik's products was again good.
However, volumes were slightly lower than in the third quarter of 2014 as a consequence of routine plant maintenance.